Company news

Botanix Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Notification regarding unquoted securities - BOT

April 14, 2022

Canine Atopic Dermatitis Program Launched

September 28, 2021

Final Report and Annual Report to Shareholders

August 26, 2021

New Canine Pilot Study Supports Further AD Investigation

May 16, 2021

Botanix Update on BTX 1801 Clinical Development

May 3, 2021

BTX 1702 Rosacea Study Approval

March 29, 2021

Botanix receives A$6.87m R&D Tax Incentive Refund

February 11, 2021

Phase 2a Study Shows BTX 1801 Eradicates S. Aureus

February 2, 2021

Antimicrobial Data Published in Peer-Reviewed Journal

January 19, 2021

Update on BTX 1801 Phase 2a Clinical Study

December 13, 2020

FDA Clears Development Path for BTX 1801

November 10, 2020

Response to ASX Price Query

September 29, 2020

New Antimicrobial Data and Conference Presentation

September 7, 2020

Appendix 4E and Annual Report to Shareholders

August 31, 2020

BTX 1801 Phase 2a Antimicrobial Study Underway

August 11, 2020

Response to ASX Aware Query

July 22, 2020

BTX 1503 End of Phase 2 Milestone with FDA

July 16, 2020

FDA Grants BTX 1801 QIDP Designation Status

April 23, 2020

Botanix Provides Update on Development Activities Amended

April 16, 2020

Botanix Provides Update on Development Activities

April 15, 2020

Botanix Announces Top Line BTX 1204 Atopic Dermatitis Data

March 24, 2020

Antimicrobial Platform Update and Launch of BTX 1801 Study

March 12, 2020

Botanix Initiates BTX 1702 Rosacea Study

December 8, 2019

Botanix Announces De-scheduling of Synthetic CBD

November 24, 2019

Botanix Announces BTX 1503 Data and Progression to Phase 3

October 22, 2019

BOT Receives Grant for Synthetic Cannabidiol Analog Program

October 14, 2019

Botanix announces new clinical program to target rosacea

September 15, 2019

Appendix 4E and Annual Report

August 19, 2019

Botanix $40 Million US Lead Placement and Management Update

July 31, 2019

Botanix Antimicrobial Platform Addresses Global Threat

July 14, 2019

BTX 1801 Kills Superbugs Without Resistance World-First

June 19, 2019

Study Confirms Anti-inflammatory and Other Properties of CBD

June 18, 2019

Pause in Trade

June 17, 2019

Dermatology Industry Leader Joins Botanix

May 19, 2019

Botanix Provides Retraction in Presentation

May 16, 2019

Pause In Trading

May 15, 2019

Permetrex Outperforms Other CBD Topical Products

February 25, 2019

Investigators Meeting Completed for BTX 1204 Phase 2 Study

January 24, 2019

Ethics Approval for Phase 2 Atopic Dermatitis Study Received

December 17, 2018

Botanix receives A$4.6m R&D Tax Incentive refund

November 22, 2018

First Patient Treated in BTX 1308 Psoriasis Patient Study

November 6, 2018

Ethics Approval for BTX 1308 Psoriasis Patient Study Secured

September 26, 2018

Botanix BTX 1503 Clinical Trial Update

September 12, 2018

FDA Clears Development Path for BTX 1204

August 29, 2018

Investigators Meeting Completed for BTX 1503 Phase 2 Trial

July 22, 2018

Botanix Joins with UQ to Accelerate Development of BTX 1801

July 18, 2018

Botanix update on development pipeline products

July 1, 2018

First Patients Recruited into BTX 1503 Phase 2 Acne Trial

June 26, 2018

BOT Welcomes First FDA Approval for Cannabidiol Product

June 25, 2018

Botanix Raises A$8m in Oversubscribed Placement

June 20, 2018

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 62 decks. Every deck is listed under its year.